E-GEOD-14468 - Transcription profiling of human newly diagnosed AML CEBPA double and single mutant and CEBPA wild type AML

Released on 23 January 2009, last updated on 12 October 2011
Homo sapiens
Samples (526)
Array (1)
Protocols (2)
Mutations in CCAAT/enhancer binding protein alpha (CEBPA) are seen in 5-14% of acute myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most AMLs with CEBPA mutations simultaneously carry two mutations (CEBPAdouble-mut), usually biallelic, while single heterozygous mutations (CEBPAsingle-mut) are less frequently seen. Using denaturing high performance liquid chromatography and nucleotide sequencing we identified among a cohort of 598 newly diagnosed AMLs a subset of 41 CEBPA mutant cases, i.e. 28 CEBPAdouble-mut and 13 CEBPAsingle-mut cases. CEBPAdouble-mut associated with a unique gene expression profile as well as favorable overall and event-free survival, retained in multivariable analysis that included cytogenetic risk, FLT3-ITD and NPM1 mutation, white blood cell count and age. In contrast, CEBPAsingle-mut AMLs did not express a discriminating signature and could not be distinguished from wild type cases as regards clinical outcome. These results demonstrate significant underlying heterogeneity within CEBPA mutation positive AML with prognostic relevance. Experiment Overall Design: Gene expression profiling of 524 cases of de novo AML. Comparisons of cases with double and single CEBPA mutations versus those with wild type CEBPA.
Experiment types
transcription profiling by array, unknown experiment type
Investigation descriptionE-GEOD-14468.idf.txt
Sample and data relationshipE-GEOD-14468.sdrf.txt
Raw data (14)Click to browse raw data
Processed data (2)E-GEOD-14468.processed.1.zip, E-GEOD-14468.processed.2.zip
Array designA-AFFY-44.adf.txt
R ExpressionSetE-GEOD-14468.eSet.r